3B BlackBio Dx Ltd

3B BlackBio Dx Other Announcement

3B BlackBio Dx sent a Reg 36(1)(b) letter to shareholders providing the weblink to its FY 2025-26 Annual Report ahead of the 54th AGM. No financial figures or business events are disclosed.

3B BlackBio Dx Annual Report

3B BlackBio Dx Ltd filed its FY 2025-26 Annual Report with BSE under Regulation 34(1). The report recaps its molecular diagnostics growth and global expansion.

3B BlackBio Dx Annual General Meeting

3B BlackBio Dx Ltd issued notice for its 54th AGM on 29 September 2026. Proposed business includes FY26 financials adoption and Rs.5 per share final dividend.

3B BlackBio Dx Other Announcement

3B Blackbio Dx Limited has appointed M/s. Sanjay Kasliwal & Associates as the Cost Auditor for the company.

3B BlackBio Dx Investor Presentation: Key Takeaways

3B BlackBio Dx reported Q1FY27 consolidated revenue of ₹33.49 Cr, up 50% YoY, driven by the Coris BioConcept acquisition. Core MDx business grew 17.4% excluding Coris.

Call

Guides 18% growth

3B BlackBio Dx Q1 FY27 Results: Net Profit ₹9 Cr, Down 28.6% YoY

3B BlackBio Dx Ltd reported revenue from operations of ₹33.5 Cr (+50.9% YoY) and net profit of ₹9 Cr (-28.6% YoY) for Q1 FY27.

Key figure

Net profit ₹9 Cr · -28.6% YoY

3B BlackBio Dx Board Meeting Date

3B BlackBio Dx Ltd has scheduled a board meeting for August 13, 2026. The board will consider unaudited financial results for the quarter ended June 30, 2026.